/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the U.S. Food and Drug Administration.
/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced its commitment to achieve net zero.
Astella goes “aggressive” with new CEO appointment; AbbVie plans to lift $2 billion cap on deals; Biogen, Sage receive NDA from Food and Drug Administration for zuranolone.